Virtual Library

Start Your Search

E.E.C. De Jong



Author of

  • +

    P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P3.01-044 - FDG-PET/CT Based Response Prediction of Stage IV NSCLC Treated with Paclitaxel-Carboplatin-Bevacizumab with or without Nitroglycerin (ID 1229)

      09:30 - 09:30  |  Author(s): E.E.C. De Jong

      • Abstract
      • Slides

      Background:
      A prospective study in stage IV non-small cell lung cancer (NSCLC) patients was performed to assess the predictive value of early response of the primary tumor evaluated by [18F]FDG-PET/CT to bevacizumab containing combination therapy with or without nitroglycerin (NTG) patches as first line treatment. NTG is a vasodilator which is hypothesized to increase tumor blood flow thereby decrease hypoxia, and 1) leading to a decrease in [18F]FDG uptake, and 2) facilitating early response assessment using [18F]FDG to predict treatment outcome.

      Methods:
      In total, 223 patients were randomized between carboplatin-paclitaxel-bevacizumab (PCB) with or without NTG (day -2 to +3; NVALT12 trial, NCT01171170). 78 patients were available for image analysis having undergone an [18F]FDG-PET/CT scan prior to the first cycle of chemotherapy and a second (optional) [18F]FDG-PET/CT scan at day 1-2 after start of the second cycle. The primary gross tumor volume (GTV) was delineated on both PET/CT scans. On the [18F]FDG-PET scan, the maximum standardized uptake value (SUV), mean SUV, peak SUV and total lesion glycolysis (TLG defined as SUVmean*CTvolume) were calculated and correlated with progression-free survival (PFS) and overall survival (OS). Early response assessment was quantified using relative changes in [18F]FDG-PET uptake parameters of the GTV expressed as delta. The median of the parameter of interest was used as cut-off value for both study arms for analysis using cox regression. Furthermore response was assessed according to PERCIST and RECIST.

      Results:

      Hazard ratio os SUV parameters > versus < the median for PFS and OS
      SUV parameter median PFS OS
      HR (p-value) 95% CI HR (p-value) 95% CI
      Delta PCB+NTG (%) SUVmax 40.4 1.026 (0.408) 0.966-1.090 1.006 (0.844) 0.945-1.071
      SUVmean 39.9 1.048 (0.127) 0.987-1.113 1.034 (0.279) 0.973-1.099
      SUVpeak 42.3 1.035 (0.258) 0.975-1.100 1.016 (0.615) 0.955-1.082
      TLG 64.5 1.064 (0.043) 1.002-1.131 1.039 (0.221) 0.977-1.106
      Delta PCB (%) SUVmax 53.2 1.027 (0.454) 0.957-1.103 1.009 (0.810) 0.939-1.084
      SUVmean 51.6 1.027 (0.465) 0.957-1.102 1.011 (0.766) 0.941-1.086
      SUVpeak 53.9 1.040 (0.281) 0.969-1.116 1.018 (0.623) 0.947-1.094
      TLG 75.9 0.994 (0.873) 0.927-1.066 0.998 (0.951) 0.928-1.072
      1) On average no decrease in [18F]FDG-PET uptake was observed for the experimental NTG group. However, patients in the experimental group showed a significantly larger variation in most SUV parameters of the second PET/CT scan compared to control group without NTG. 2) In table 1 the hazard ratios are shown for the relative delta SUVmax, SUVmean, SUVpeak and TLG for both study arms. In the experimental group, patients with a small delta TLG (<64%) had a shorter PFS than patients with a larger change in TLG (HR:1.064; 95% CI 1.002-1.131; p=0.043). Response assessed by PERCIST and RECIST did not predict for a longer PFS or OS.

      Conclusion:
      Adding NTG did not result in a decrease in [18F]FDG-PET uptake compared to patients without NTG although NTG increased variability of the measured SUV parameters. Patients in the experimental NTG arm without an early response on [18F]FDG-PET/CT imaging had a worse PFS than patients with a response. For the group without NTG no difference was observed. Also, RECIST and PERCIST were not predictive.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.